Overview

Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer

Status:
Terminated
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
Phase II Study of Maintenance Tarceva (Erlotinib) in patients with locally advanced Head and Neck Cancer after treatment with curative intent
Phase:
Phase 2
Details
Lead Sponsor:
Geisinger Clinic
Collaborator:
Genentech, Inc.
Treatments:
Erlotinib Hydrochloride